The TATA-binding protein (TBP) plays a central role in assembling eukaryotic transcription complexes and is subjected to extensive regulation including auto-inhibition of its DNA binding activity through dimerization. Previously, we have shown that mutations that disrupt TBP dimers in vitro have three detectable phenotypes in vivo, including decreased steady-state levels of the mutants, transcriptional derepression, and toxicity toward cell growth. In an effort to more precisely define the multimeric structure of TBP in vivo, the crystallographic dimer structure was used to design mutations that might enhance dimer stability. These mutations were found to enhance dimer stability in vitro and significantly suppress in vivo phenotypes arising from a dimer-destabilizing mutation. Although it is conceivable that phenotypes associated with dimer-destabilizing mutants could arise through defective interactions with other cellular factors, intragenic suppression of these phenotypes by mutations designed to stabilize dimers provides compelling evidence for a crystallographic dimer configuration in vivo.Gene expression levels are derived from a net output of a dynamic interplay of positive and negative regulatory factors. The main steps leading toward gene activation include chromatin modification and remodeling, TBP 1 delivery, and assembly of the RNA polymerase II holoenzyme (1-3). Each of these steps is the target of multiple regulatory factors. TBP delivery to promoters is directed by the positive action of transcriptional activators, acetylated histone tails, SAGA and TFIID delivery complexes, basal factors such as TFIIA and TFIIB, and the TATA box. Counteracting this delivery are Mot1, NC2, a portion of TAF1 (termed TAND), the amino-terminal domain of TBP, and TBP auto-inhibition, which occurs through dimerization and occlusion of its DNA binding surface.TBP auto-inhibition through dimerization is an evolutionary conserved process, occurring from yeast to mammals (4 -15). The structure of TBP dimers has been defined crystallographically and through biochemical analysis. Dimer instability caused by mutations along the crystallographic dimer interface correlate with transcriptional derepression in yeast cells (8,15), and this derepression occurs genome-wide at about 7% of all genes (16). Together, these findings indicated that TBP dimerization represents a physiologically important mechanism for auto-inhibiting its DNA binding activity. Nonetheless, the notion of an autoinhibited TBP dimer has been sufficiently controversial (17) that we pursued the possibility of using the x-ray crystal structure of TBP dimers to design stabilizing mutations that might intragenically suppress a dimerization mutant.We focused on two residues, Arg-98 and Arg-171, which lie on opposite sides of a TBP monomer. In the dimer configuration, Arg-98 of one monomer lies immediately across Arg-171 of the opposing monomer (11). We reasoned that changing one or the other to an acidic residue might generate a positive electrostatic interaction wh...